FDA Approves Novo Nordisk's Rybelsus Diabetes Pill to Reduce Heart Risk

Dow Jones

2025/10/18

By Nicholas G. Miller

The Food and Drug Administration approved Novo Nordisk's oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes.

The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat type 2 diabetes but under the new approval, Novo Nordisk can now market the drug's benefits of reducing cardiovascular events.

European regulators granted Rybelsus similar approval earlier this year.

The FDA approval is based on a Phase 3 trial that found that the drug reduced the risk of major adverse cardiovascular events by 14% over four years among high-risk adults with type 2 diabetes.

The company has also submitted an application for its Wegovy drug to be approved for the treatment of obesity. A decision is expected later this year.

Write to Nicholas G. Miller at nicholas.miller@wsj.com

(END) Dow Jones Newswires

October 17, 2025 17:55 ET (21:55 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2576062232"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576062232\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576062232?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-18 05:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576062232","market":"fut","top_or_hot":-1,"title":"FDA Approves Novo Nordisk's Rybelsus Diabetes Pill to Reduce Heart Risk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  The Food and Drug Administration approved <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes. \n</p>\n<p>\n  The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat type 2 diabetes but under the new approval, Novo Nordisk can now market the drug's benefits of reducing cardiovascular events. \n</p>\n<p>\n  European regulators granted Rybelsus similar approval earlier this year. \n</p>\n<p>\n  The FDA approval is based on a Phase 3 trial that found that the drug reduced the risk of major adverse cardiovascular events by 14% over four years among high-risk adults with type 2 diabetes. \n</p>\n<p>\n  The company has also submitted an application for its Wegovy drug to be approved for the treatment of obesity. A decision is expected later this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 17, 2025 17:55 ET (21:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approves Novo Nordisk's Rybelsus Diabetes Pill to Reduce Heart Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approves Novo Nordisk's Rybelsus Diabetes Pill to Reduce Heart Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-18 05:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  The Food and Drug Administration approved <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes. \n</p>\n<p>\n  The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat type 2 diabetes but under the new approval, Novo Nordisk can now market the drug's benefits of reducing cardiovascular events. \n</p>\n<p>\n  European regulators granted Rybelsus similar approval earlier this year. \n</p>\n<p>\n  The FDA approval is based on a Phase 3 trial that found that the drug reduced the risk of major adverse cardiovascular events by 14% over four years among high-risk adults with type 2 diabetes. \n</p>\n<p>\n  The company has also submitted an application for its Wegovy drug to be approved for the treatment of obesity. A decision is expected later this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 17, 2025 17:55 ET (21:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2576062232","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576062232","pubTimestamp":1760738100,"columns":[{"name":"产品发布","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"The Food and Drug Administration approved Novo Nordisk's oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes.The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat type 2 diabetes but under the new approval, Novo Nordisk can now market the drug's benefits of reducing cardiovascular events.European regulators granted Rybelsus similar approval earlier this year.The FDA approval is based on a Phase 3 trial that found that the drug reduced the risk of major adverse cardiovascular events by 14% over four years among high-risk adults with type 2 diabetes.The company has also submitted an application for its Wegovy drug to be approved for the treatment of obesity. A decision is expected later this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4599":"减肥药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4007":"制药","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","NVO":"诺和诺德","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"FDA批准诺和诺德的Rybelsus糖尿病药丸可降低心脏风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.5},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  The Food and Drug Administration approved Novo Nordisk's oral GLP-1 medication to reduce the risk of major cardiovascular events in high-risk adults with type 2 diabetes. \n\n\n  The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat type 2 diabetes but under the new approval, Novo Nordisk can now market the drug's benefits of reducing cardiovascular events. \n\n\n  European regulators granted Rybelsus similar approval earlier this year. \n\n\n  The FDA approval is based on a Phase 3 trial that found that the drug reduced the risk of major adverse cardiovascular events by 14% over four years among high-risk adults with type 2 diabetes. \n\n\n  The company has also submitted an application for its Wegovy drug to be approved for the treatment of obesity. A decision is expected later this year. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 17, 2025 17:55 ET (21:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}